Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Beka Solomon

Beka Solomon, Herzlia Pituach IL

Patent application numberDescriptionPublished
20090186027SINGLE CHAIN ANTIBODIES AGAINST BETA-AMYLOID PEPTIDE - Anti-AβP scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of Abp 1-40 and disaggregate Abp 1-40 fibrils generated in vitro. The anti-Aβp scFv antibodies also stained amyloid neuritic plaques on slices from transgenic mice. The anti-ABP scFv and single domain antibodies can be used for inhibiting or treating Alzheimer's disease.07-23-2009
20090304726VIRAL DISPLAY VEHICLES FOR TREATING MULTIPLE SCLEROSIS - Provided are viral display vehicles which display multiple sclerosis associated antigens on the surface thereof for induction of immune tolerance to autoantigens such as MOG. Also provided are methods and pharmaceutical compositions for treating multiple sclerosis using the viral display vehicles of the present invention.12-10-2009
20090317324FILAMENTOUS BACTERIOPHAGE DISPLAYING PROTEIN AS A BINDER OF ANTIBODIES AND IMMUNOCOMPLEXES FOR DELIVERY TO THE BRAIN - The present invention relates to a phage display vehicle composed of a filamentous bacteriophage displaying on its surface, as a non-filamentous bacteriophage molecule, protein A or a fragment or variant thereof capable of binding the Fc portion of antibodies, and an antibody or an antigen-antibody immunocomplex bound to protein A or a fragment or variant thereof by its Fc portion. The phage display vehicle is formulated into a pharmaceutical composition and can be used to treat/inhibit or to diagnose a brain disease, disorder or condition.12-24-2009
20100074908Human synthetic single-chain antibodies directed against the common epitope of mutant P53 and their uses - Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptosis and treating cancer as well as diagnosing a p53-related cancer using the isolated polypeptides uncovered by the present invention.03-25-2010
20110070249IMMUNIZING COMPOSITION AND METHOD FOR INDUCING AN IMMUNE RESPONSE AGAINST THE Beta-SECRETASE CLEAVAGE SITE OF AMYLOID PRECURSOR PROTEIN - The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AβPP epitope spanning the β-secretase cleavage site of AβPP and a method for inducing an immune response against the β-secretase cleavage site of AβPP using this immunizing composition. The present invention is also directed to antibodies against the β-secretase cleavage site of AβPP and their use in a method for inhibiting the formation of amyloid β.03-24-2011
20110262447HUMAN SYNTHETIC SINGLE-CHAIN ANTIBODIES DIRECTED AGAINST THE COMMON EPITOPE OF MUTANT P53 AND THEIR USES - Isolated polypeptides, isolated polynucleotides or expression vectors encoding same, viral display vehicles which can be specifically bind an exposed epitope shared by mutant, but not wild type, p53 protein are provided. Also provided are methods of inducing apoptosis and treating cancer as well as diagnosing a p53-related cancer using the isolated polypeptides uncovered by the present invention.10-27-2011

Patent applications by Beka Solomon, Herzlia Pituach IL

Beka Solomon, Herzliyz IL

Patent application numberDescriptionPublished
20090324554METHOD FOR INHIBITING OR TREATING A DISEASE ASSOCIATED WITH INTRACELLULAR FORMATION OF PROTEIN FIBRILLAR OR AGGREGATES - A therapeutic agent which carries a peptide sequence containing a mammalian cell adhesion sequence can be used to inhibit or treat diseases associated with intracellular formation of protein fibrillar inclusions or aggregates, to inhibit the intracellular formation of protein fibrillar inclusions or aggregates, and to disaggregate pre-formed intracellular protein fibrillar inclusions or aggregates. Filamentous bacteriophage which displays a non-filamentous bacteriophage RGD cell adhesion sequence on its surface, but not an antibody or non-filamentous bacteriophage antigen other than said RGD cell adhesion sequence, is a preferred embodiment of such a therapeutic agent.12-31-2009

Beka Solomon, Herzilia Pituach IL

Patent application numberDescriptionPublished
20090280114PREVENTION OF BRAIN INFLAMMATION AS A RESULT OF INDUCED AUTOIMMUNE RESPONSE - A disease characterized by amyloid aggregation in a patient may be prevented or treated by causing antibodies against a peptide component of the amyloid deposit to come into contact with the aggregated or soluble amyloid. In order to decrease the risk of inflammation in such a method, the Fc receptors of the patient are blocked, preferably by administration of an effective amount of IVIg, prior to the procedure of causing the antibodies to come into contact with the amyloid.11-12-2009
20110142858Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation - Unglycosylated anti-amyloid antibodies maintained all the antigen recognition functions of the native glycosylated anti-amyloid antibodies but without, or with a much reduced, property of triggering Fc receptor-mediated inflammation response in the brain. Such unglycosylated antibodies can be used in a method for preventing, inhibiting, or treating a disease or disorder characterized by amyloid aggregation with a diminished risk of triggering or exacerbating neuroinflammation.06-16-2011

Patent applications by Beka Solomon, Herzilia Pituach IL

Beka Solomon, Herzliya IL

Patent application numberDescriptionPublished
20090180991METHOD FOR TREATING INFLAMMATION ASSOCIATED WITH AMYLOID DEPOSITS AND BRAIN INFLAMMATION INVOLVING ACTIVATED MICROGLIA - Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits.07-16-2009
20110142803METHOD FOR TREATING INFLAMMATION ASSOCIATED WITH AMYLOID DEPOSITS AND BRAIN INFLAMMATION INVOLVING ACTIVATED MICROGLIA - Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits.06-16-2011

Beka Solomon, Herzila Pituach IL

Patent application numberDescriptionPublished
20080241169IMMUNIZATION AGAINST AMYLOID PLAQUES USING DISPLAY TECHNOLOGY - A strategy for immunizing against amyloid plaques using display technology. The strategy includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antigen or epitope on a display vehicle. The strategy further includes methods, agents, and pharmaceutical compositions for vaccination against plaque forming diseases (e.g., Alzheimer's disease) that rely upon presentation of an antibody, or an active portion thereof, on a display vehicle. Whether antigens or antibodies are employed, desegregation of plaques results from the immunization.10-02-2008

Beka Solomon, Herzliyza IL

Patent application numberDescriptionPublished
20110182948METHOD FOR TREATING DISEASE CHARACTERIZED BY PLAQUE - The present invention relates to the use of a filamentous agent other than a filamentous bacteriophage to disaggregate aggregated proteins in plaque or to treat a patient suffering from or susceptible to a disease characterized by the presence of plaque.07-28-2011

Beka Solomon, Herzliya Pituach Herzliya IL

Patent application numberDescriptionPublished
20110286970METHOD FOR TREATING PARKINSON'S DISEASE - The present invention relates to the use of a filamentous bacteriophage, which displays an antibody that specifically binds to a pro-inflammatory cytokine, either alone or in combination with a filamentous bacteriophage that does not display a mammalian cell internalization signal, to treat Parkinson's disease.11-24-2011